ADEKUNLE ADEGBITE: Open Payments
NPI 1407494735 · RIVERSIDE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,448 in 190 payments from 13 companies in 2025. Trend: 2023 $2,179 · 2024 $2,048 · 2025 $3,448
Food & beverage: $3,448
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 48 | $950 |
| Otsuka America Pharmaceutical, Inc. | 23 | $468 |
| Neurocrine BioSciences, Inc. | 18 | $331 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $285 |
| E.R. Squibb & Sons, L.L.C. | 17 | $272 |
| Teva Pharmaceuticals USA, Inc. | 17 | $270 |
| Alkermes, Inc. | 15 | $230 |
| Janssen Pharmaceuticals, Inc | 13 | $230 |
| Collegium Pharmaceutical, Inc. | 15 | $147 |
| Lundbeck LLC | 8 | $146 |
Products named: VRAYLAR, REXULTI, INGREZZA, CAPLYTA, COBENFY, AUSTEDO XR, INVEGA SUSTENNA, ARISTADA.
Industry payments across CA — which companies pay providers there.
